Características clínico-epidemiológicas de pacientes con síndrome de Guillain-Barré y COVID-19: Revisión Sistemática
Descripción del Articulo
There is evidence that SARS-CoV-2, the COVID-19 virus, is related as a predisposing factor or as a trigger with direct demyelinating pathophysiology in Guillain Barre Syndrome (GBS). Objective: To describe the clinical-epidemiological characteristics of patients with Guillain- Barre syndrome and COV...
Autor: | |
---|---|
Formato: | tesis de grado |
Fecha de Publicación: | 2022 |
Institución: | Universidad Nacional de Trujillo |
Repositorio: | UNITRU-Tesis |
Lenguaje: | español |
OAI Identifier: | oai:dspace.unitru.edu.pe:20.500.14414/18478 |
Enlace del recurso: | https://hdl.handle.net/20.500.14414/18478 |
Nivel de acceso: | acceso abierto |
Materia: | Síndrome de Guillain Barré, COVID-19 SARS-CoV-2 Polirradiculoneuropatía Aguda Inflamatoria |
Sumario: | There is evidence that SARS-CoV-2, the COVID-19 virus, is related as a predisposing factor or as a trigger with direct demyelinating pathophysiology in Guillain Barre Syndrome (GBS). Objective: To describe the clinical-epidemiological characteristics of patients with Guillain- Barre syndrome and COVID-19. Methods: Systematic review-type secondary research without meta-analysis (n=106), selected from 88 articles, where the clinical-epidemiological data were extracted, generating a database, percentages, averages, minimum and maximum values were calculated for the preparation of tables. Results: It occurred mainly in men, in patients with an average age of 52.94 years, it occurred within the first 10 days in 45.28%, the form of ascending presentation was the most common with 63.21%, as well as the AIDP variant in 55.66%, 29.25% required mechanical ventilation, with the most common comorbidity being hypertension (28.72%) and the most used treatment immunoglobulin IV (86.79%). Conclusion: GBS in COVID-19 occurs mainly in men, over 50 years of age, with the ascending, demyelinating variant being the most frequent, the use of immunoglobulin being the most frequent, and having a high recovery rate. |
---|
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).